Clinical trials are divided into several phases to ensure the safety and effectiveness of new medical interventions, such as drugs, treatments, or medical devices, before they are approved for widespread use. Here are the typical phases of clinical trials:
Phase 0: Exploratory Study
Phase 0 trials are relatively new and not always a part of the clinical trial process. They involve a small number of participants and aim to gather initial data on how the drug or treatment behaves in the human body. These trials help researchers decide whether to move forward with larger Phase 1 trials.
Phase 1: Safety and Dosage Study
Phase 1 trials involve a small number of healthy volunteers or patients and focus on assessing the safety of the intervention and determining the appropriate dosage range. Researchers closely monitor participants for any adverse effects, evaluate how the intervention is metabolized, and gather initial data on its efficacy.
Phase 2: Expanded Safety and Efficacy Study
Phase 2 trials involve a larger number of patients who have the condition the intervention is intended to treat. These trials continue to assess safety, evaluate dosage regimens, and gather more data on the intervention's efficacy. Researchers may also explore different patient populations, dosages, or combinations with other treatments.
Phase 3: Confirmatory Study
Phase 3 trials are large-scale studies involving a significant number of patients to confirm the intervention's safety, effectiveness, and monitor any side effects. These trials often include a randomized and controlled design, comparing the new intervention against existing standard treatments or placebos. Phase 3 trials provide critical data for regulatory agencies to evaluate whether the intervention should be approved for widespread use.
Phase 4: Post-Marketing Surveillance Study
Phase 4 trials take place after the intervention has received regulatory approval and is available to the general public. They aim to monitor the intervention's long-term safety, effectiveness, and identify any rare or long-term side effects. Phase 4 trials may involve a larger and more diverse population than earlier phases.
this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about c
Clinical trials are divided into several phases to ensure the safety and effectiveness of new medical interventions, such as drugs, treatments, or medical devices, before they are approved for widespread use. Here are the typical phases of clinical trials:
Phase 0: Exploratory Study
Phase 0 trials are relatively new and not always a part of the clinical trial process. They involve a small number of participants and aim to gather initial data on how the drug or treatment behaves in the human body. These trials help researchers decide whether to move forward with larger Phase 1 trials.
Phase 1: Safety and Dosage Study
Phase 1 trials involve a small number of healthy volunteers or patients and focus on assessing the safety of the intervention and determining the appropriate dosage range. Researchers closely monitor participants for any adverse effects, evaluate how the intervention is metabolized, and gather initial data on its efficacy.
Phase 2: Expanded Safety and Efficacy Study
Phase 2 trials involve a larger number of patients who have the condition the intervention is intended to treat. These trials continue to assess safety, evaluate dosage regimens, and gather more data on the intervention's efficacy. Researchers may also explore different patient populations, dosages, or combinations with other treatments.
Phase 3: Confirmatory Study
Phase 3 trials are large-scale studies involving a significant number of patients to confirm the intervention's safety, effectiveness, and monitor any side effects. These trials often include a randomized and controlled design, comparing the new intervention against existing standard treatments or placebos. Phase 3 trials provide critical data for regulatory agencies to evaluate whether the intervention should be approved for widespread use.
Phase 4: Post-Marketing Surveillance Study
Phase 4 trials take place after the intervention has received regulatory approval and is available to the general public. They aim to monitor the intervention's long-term safety, effectiveness, and identify any rare or long-term side effects. Phase 4 trials may involve a larger and more diverse population than earlier phases.
this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about clinical trials.this is a presentation about c
Post Marketing Surveillance (Regulatory affairs).pptxYuvaraj KG
Postmarketing drug surveillance refers to the monitoring of drugs once they reach the market after clinical trials. It evaluates drugs taken by individuals under a wide range of circumstances over an extended period of time.
Assignment on Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional, Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring-Safety Monitoring in CT
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
Clinical Studies - Foundational to the Drug Approval ProcessJohn Kriak
One of the key elements in gaining approval of a drug by the US Food and Drug Administration (FDA) involves clinical research. There are two primary avenues of such research: clinical trials and observational studies. The latter involves monitoring subjects within normal settings, with data gathered over time and health changes evaluated and compared with others in the group.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Post Marketing Surveillance (Regulatory affairs).pptxYuvaraj KG
Postmarketing drug surveillance refers to the monitoring of drugs once they reach the market after clinical trials. It evaluates drugs taken by individuals under a wide range of circumstances over an extended period of time.
Assignment on Experimental Study- RCT and Non RCT, Observation Study: Cohort, Case Control, Cross sectional, Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring-Safety Monitoring in CT
Definition and scope of Pharmacoepidemiology ABUBAKRANSARI2
In these slides I shared the information of definition and scope of pharmacoepidemiology. Types of studies - cohort studies, cross-sectional studies etc.
Clinical Studies - Foundational to the Drug Approval ProcessJohn Kriak
One of the key elements in gaining approval of a drug by the US Food and Drug Administration (FDA) involves clinical research. There are two primary avenues of such research: clinical trials and observational studies. The latter involves monitoring subjects within normal settings, with data gathered over time and health changes evaluated and compared with others in the group.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
1. PHASE IV CLINICAL TRIAL
Dr Abisha T
Department of Pharmacology
AIIMS Jodhpur
2. CLINICAL TRIALS
A systematic study on pharmaceutical products in human subjects (including patients and other
volunteers) in order to
◦ discover or verify the effects
◦ identify any adverse reaction to investigational products
◦ to study the absorption, distribution, metabolism and excretion
of the products with the object of ascertaining their efficacy and safety.
Guidelines for good clinical practice (GCP) for trials on pharmaceutical products
3.
4. PHASE 3 LIMITATIONS
◦ Limited sample size (few thousands).
◦ Short duration (3-5 years).
◦ Strict inclusion/exclusion criteria.
◦ No dose adjustment.
◦ No concomitant medications.
◦ Relatively uncommon side effects are likely to be missed.
◦ Special population are rarely included.
5. PHASE IV
◦ These are referred to as post-marketing surveillance studies.
◦ Phase IV studies comprise the obligatory post-marketing surveillance designed to detect any rare or
long-term adverse events resulting from the use of the approved drug in a clinical setting.
◦ Open label study.
◦ After a product has been placed on the market, clinical trials designed to explore new indications,
new methods of administration or new combinations, etc. are normally considered as trials for new
pharmaceutical products.
◦ No fixed duration.
Goodman and Gilman’s Pharmacological basis of thareapeutics
6. OBJECTIVES
⁕ Comparative long term Risk-Benefit assessment.
⁕ Long term drug usage in the community.
⁕ Quality of Life assessment.
⁕ Dose-refinement.
⁕ Rare ADR’s and long term safety.
⁕ Drug-drug interaction.
⁕ Cost-Benefit assessment.
⁕ Improvement in Primary End-points of disease.
9. I. Regulatory Authority mandated studies:
1. Drug-drug interactions.
2. Formulation advancement.
3. Special safety.
4. Special populations.
II. Non-Regulatory Authority mandated studies:
A. Randomized controlled trials:
1. Superiority versus equivalence testing.
2. Large simple trials.
3. PROBE designs.
B. Surveillance studies:
1. Pharmacovigilance studies.
2. Effectiveness studies.
3. Drug utilization studies.
4. Observational epidemiology studies.
III. Health services research (HSR).
IV. Health outcomes research (HOR).
10. Regulatory Authority mandated studies
A. Drug-drug interactions:
◦ Unanticipated, unrecognized, or mismanaged DDIs are an important cause of morbidity and mortality
associated with prescription drug use and have occasionally caused the withdrawal of approved drugs from
the market.
◦ Clinically relevant DDIs between an investigational drug and other drugs should therefore be:
(1) defined during drug development as part of assessment of the investigational drug’s benefits and risks.
(2) understood via nonclinical and clinical assessment at the time of the investigational drug’s approval.
(3) monitored after approval.
(4) communicated in the labeling.
11. ◦ For example, Terfenadine, a once-popular antihistamine, was removed from the market
because its metabolism was inhibited by CYP3A4 substrates such as erythromycin and
grapefruit juice.
◦ When DDI information has direct implications for the safe and effective use of the drug, this
information is often included in varying levels of detail in other sections of the labeling (e.g.,
boxed warning, dosage and administration, contraindications and warnings and precautions
sections)
12. B. Formulation advancement:
◦ Ease of drug administration, safety, affordability and efficacy are the major concerns in
pharmacotherapy leading to exploration of better drug delivery systems.
◦ Different carriers used in new drug delivery systems are liposomes, microspheres (intramuscular) and
nanoparticles (intravenous), pegylated proteins, polymeric gels, implants and anti-IgE monoclonal
antibody.
◦ For example, Diclofenac is available in stomach acid-resistant formulations (25 and 50 mg), fast-
disintegrating oral formulations (25 and 50 mg), powder for oral solution (50 mg), slow- and controlled-
release forms (75, 100 or 150 mg), suppositories (50 and 100 mg), trans-dermal patches (100 and
200mg) and injectable forms (50 and 75 mg).
13. C. Special safety:
Meta analysis can be done
-to evaluate a safety endpoint by statistical analysis of data from completed studies or clinical trials.
-to evaluate
◦ occurrence of all-cause mortality.
◦ cardiovascular death.
◦ cancer incidence.
◦ identify potential predictive factors.
in patients treated with the drug compared to control therapies in all completed randomized clinical
trials that include the drug.
14. D. Special population:
◦ Special populations which include women (non-pregnant and pregnant), pediatrics and the
elderly require additional consideration with regard to clinical research.
◦ The definition of ‘‘special population’’ exists to provide enhanced awareness of their
vulnerabilities, thereby allowing the creation of regulatory guidance aimed to decrease injury
or outright harm.
◦ There are very specific regulatory laws, which protect these special populations, that need to be
understood and adhered to in order to perform clinical research.
15. Women and pregnant population:
◦ One of the primary mandates of the regulatory authority was for the investigation of gender differences
related to drug safety and efficacy.
◦ In addition to tracking the rate of women participating in clinical trials and providing education, the office
of women health (OWH) under the regulatory authority funds a wide variety of studies to better
understand the role of gender and health.
◦ The OWH encompasses the mission of advancing the understanding of gender and health to the state of
pregnancy.
◦ Pregnant women very often receive or take medication and therefore, warrant protection from ‘‘off-label’’
experimentation by being included in the process of clinical trials where relevant.
◦ The Regulatory authority hosts a list of Pregnancy Exposure Registries which has information on drugs
and vaccines for pregnant women. Although, the registries are a great resource to find what data exist and
is being actively collected, drug information concerning pregnant women is frequently unavailable.
Therefore, many registries are seeking pregnant women for participation in a clinical study.
16. Paediatric population:
◦ The Code of Federal Regulations (CFR) states that research may include children if
(a) No greater than minimal risk to children is presented.
(b) Adequate provisions are made for soliciting the assent of the children and the permission of their
parents or guardians.
◦ There are two more categories of research as it applies to children:
(1) Research involving interventions or procedures that present a minor increase over minimal risk
without the prospect of direct benefit to the individual participant, but is likely to produce generalizable
knowledge about the child’s disorder or condition.
(2) Research which presents an opportunity to understand, prevent, or alleviate a serious problem
affecting the health or welfare of children. Research in this category must be reviewed and approved by the
regulatory authority.
17. Geriatric population:
◦ Regulatory authority recommends that drug sponsors include elderly people (>65 years) in
clinical trials, as well as requiring that drug sponsors report data by age.
◦ Individuals with Decisional Impairment are those who have diminished capacity for
understanding information or making a reasoned decision due to a cognitive or emotional
disorder.
◦ A legally authorized representative (LAR) may consent for these individuals to participate in
research studies. The LAR may be the spouse of a married person or any adult child.
18. II. Non-Regulatory Authority-mandated studies:
A. Randomized controlled trials:
1. Superiority versus equivalence testing.
2. Large simple trials.
3. PROBE designs.
20. SUPERIORITY TRIAL
o Demonstration of improved efficacy of a new treatment over
placebo/standard treatment meeting statistical significance.
o For serious illnesses, when a therapeutic treatment which has been
shown to be efficacious by superiority trial exists, a placebo-
controlled trial may be considered unethical. In that case the
scientifically sound use of standard treatment as a control should be
considered.
21. ◦ Example, PLATO - To determine whether ticagrelor is superior to clopidogrel for the prevention
of vascular events and death in a broad population of patients presenting with an acute
coronary syndrome. The cardio-vascular death (primary end point) was significantly less with
ticagrelor treatment when compared to clopidogrel treatment.
22. EQUIVALENCE TRIAL
◦ Demonstration of the absolute reduction of events achieved by one
treatment is similar to that achieved by another treatment. A trial
with primary objective of showing that the response to two or more
treatments differs by an amount which is clinically unimportant.
◦ For an equivalence trial, it is necessary to determine a “zone of
clinical equivalence” prior to the trial onset.
23. ◦ For example, consider standard and experimental anti-hypertensive drugs. Suppose that the
standard drug yields a mean reduction of 5 mm Hg in diastolic blood pressure for a certain
patient population. The investigator may decide that the experimental drug is clinically
equivalent to the standard drug if its mean reduction in diastolic blood pressure is 3-7 mm Hg.
This is based on clinical judgment and there may be differences of opinion on this 'arbitrary'
level of equivalence.
◦ Unlike a placebo-controlled trial, equivalence trial does not provide a natural check for internal
validity because equivalence of the experimental and active control therapies does not
necessarily imply that either of them is effective.
25. ◦ Sometimes, an already marketed drug needs to be evaluated for a different condition than
existed for its approval or at a different dose, different release system, and so on.
◦ In that instance, the regulatory authority might mandate a phase IV RCT that has all the
characteristics of a classic phase III design.
◦ The concept of large simple clinical trials is to demonstrate even modest benefits of an
intervention, particularly in common conditions.
◦ The presumption in this trial is that the benefits are similar across participant types, so that the
entry criteria can be broad, and the data entry and management can be simplified, thereby
reducing the cost.
26. ◦ This model further depends on a relatively easily administered intervention and an easily
ascertained outcome.
◦ If these criteria are met, the size of the study also allows for a large enough sample size to
assess less common ADEs.
◦ For example, The Clinical Trial of Reviparin and Metabolic Modulation of Acute Myocardial
Infarction (CREATE). In this trial, more than 20,000 subjects from 21 countries were enrolled
to compare 2 therapies: glucose-insulin-potassium infusion and low molecular weight heparin.
28. ◦ A variation of the Large Simple Trial (LST) that also addresses a more “real-world” principle.
◦ By using open-label therapy, the drug intervention and its comparator can be clinically titrated,
as would occur in a doctor’s office, as compared to the fixed dosing of most RCTs.
◦ Blinding is maintained as to the outcome.
◦ To test whether the use of open-label versus double-blind therapy affected outcomes
differentially, a meta-analysis of PROBE trials and double-blind trials in hypertension was
reported by Smith et al. They found that changes in mean ambulatory blood pressure from
double-blind controlled studies and PROBE trials were statistically equivalent.
29. II. Non-Regulatory Authority-mandated studies:
B. Surveillance studies:
1. Pharmacovigilance studies.
2. Effectiveness studies.
3. Drug utilization studies.
4. Observational epidemiology studies.
31. ◦ Pharmacovigilance is the science and activities relating to the Detection, Assessment,
Understanding and Prevention of adverse effects or any other possible drug-related problems.
◦ It is known that in the occurrence of adverse drug reactions, other factors are involved, such as
the individual variation in pharmacogenetic profiles, drug metabolic pathways, the immune
system, and drug-drug interactions.
◦ In addition, the dose range established in clinical trials is not always representative of that used
in the post-marketing phase.
◦ Wider variety of dosages and diverse populations needs to be included in the premarketing
phase, and/or additional studies should be requested and enforced in the post-marketing phase.
32. Aim of Pharmacovigilance
• To improve patient care & safety in relation to
medicines & all medical & para-medical interventions
Patient Care
• To improve public health & safety in relation to the use
of medicines
Public Health
• To contribute to the assessment of benefit, harm,
effectiveness and risk of medicines
Risk Benefit Assessment
• To promote understanding, clinical training & effective
communication to health professionals & the public
Communication
34. Comparative observational studies
oCross- sectional study
oCase- control study
oCohort study
Targeted Clinical Investigations
Descriptive Studies
oNatural history of disease
oDrug utilization study
35. Periodic safety update reports (PSUR)
◦ The applicant shall furnish periodic safety update reports (PSURs) in order to-
(a) report all relevant new information from appropriate sources;
(b) relate the data to patient exposure;
(c) summarise the market authorisation status in different countries and any significant variations
related to safety;
(d) indicate whether changes shall be made to product information in order to optimise the use of
product.
◦ Usually all dosage forms and formulations as well as indications for new drugs should be covered in one
periodic safety update report.
36. ◦ The periodic safety update reports shall be submitted every six months for the first two years
after approval of the drug is granted to the applicant. For subsequent two years – the periodic
safety update reports need to be submitted annually.
◦ Central Licencing Authority may extend the total duration of submission of periodic safety
update reports if it is considered necessary in the interest of public health. However, all cases
involving serious unexpected adverse reactions must be reported to the licencing authority
within fifteen days of initial receipt of the information by the applicant.
◦ New studies specifically planned or conducted to examine a safety issue should be described in
the periodic safety update reports.
38. ◦ Also called “real-world studies” or “pragmatic trials ”.
◦ It measures the degree of beneficial effect under “real world” clinical settings.
◦ The greater variance caused by the different kinds of confounders as well as problematic design issues,
such as insensitive primary outcome criteria, unblinded treatment conditions, inclusion of chronic
refractory patients, etc, can lead to wrong conclusions.
◦ Due to these methodological problems, effectiveness studies are on a principally lower level of evidence,
adding only a complementary view to the results of phase III trials without falsifying their results.
39. Advantages
◦ Higher external validity.
◦ Arguably greater applicability to “real-world”
practice settings.
◦ Capacity to inform policy process.
◦ Longer duration can be easily achieved.
◦ Can enroll large number of patients more easily.
Disadvantages
◦ Internal validity limited.
◦ Cannot be used to examine effective dose
ranges.
◦ Cannot make as meaningful clinical
comparisons between agents.
41. ◦ Drug utilization studies aim to evaluate “the marketing, distribution, prescription, and use of
drugs in a society, with special emphasis on the resulting medical, social and economic
consequences”.
◦ DUS are useful to estimate the number of patients exposed to specific drugs within a given
time period.
◦ Their scope is to evaluate the present state and future trends of drug usage, to estimate crudely
disease prevalence, drug expenditures, appropriateness of prescriptions and adherence to
evidence-based recommendations.
44. ◦ Observational studies fall under the category of analytic study designs. The goal is to identify and
evaluate causes or risk factors of diseases or health-related events.
◦ Cohort studies and case-control studies are two primary types of observational studies.
◦ Randomized controlled trial methodology, which was first developed for drug trials, can be difficult to
conduct for surgical investigations. Instead, well-designed observational studies, can play an important
role in deriving evidence.
◦ Results from observational studies are often criticized for being vulnerable to the influence of
unpredictable confounding factors.
◦ However, recent work shows comparable results between observational studies and randomized
controlled trials.
◦ Observational studies can also complement randomized controlled trials in hypothesis generation,
establishing questions for future randomized controlled trials, and defining clinical conditions.
46. ◦ Due to the complexities of health care services and systems, investigating and interpreting the
use, costs, quality, accessibility, delivery, organization, financing, and outcomes of health care
services is key to informing government officials, insurers, providers, consumers, and others
making decisions about health-related issues.
◦ Health services researchers examine the access to care, health care costs and processes, and the
outcomes of health services for individuals and populations.
◦ The goal of HSR is “to provide information that will eventually lead to improvements in the
health of the citizen.”
47. ◦ As new diagnostic and treatment technologies are introduced, HSR examines their impact on
patient outcomes of care and health care costs.
◦ Six critical elements:
◦ Patient Safety.
◦ Effectiveness.
◦ Timeliness.
◦ Patient Centred.
◦ Efficiency.
◦ Equity.
49. ◦ It is a research aimed at assessing the quality and effectiveness of health care as measured by
the attainment of a specified end result or outcome. Measures include parameters such as
improved health, lowered morbidity or mortality, and improvement of abnormal states (such as
elevated blood pressure).
◦ It aims to:
(i) provide better information to inform patient decisions.
(ii) guide health providers.
(iii) inform health policy decisions.
◦ The scope of outcome research focus on Quality-of-life measures, Effectiveness, Cost, Quality
of care, Patient preferences, Appropriateness, Access and Health status in areas such as Disease
prevention, Screening, Drug treatment, Medical procedures, Medical practices, Diagnostic
tests, Guidelines and Health-care policy.
52. BOX WARNING
◦ Approximately 20% of drugs acquire new black box warnings post-marketing.
◦ A black box warning is issued when reasonable evidence suggests an association of a
serious safety hazard with a drug product. A causal relationship does need to be established
for a black box warning to appear on a drug's labeling.
53.
54. Drugs Withdrawn From the Market
4% of the drugs were ultimately withdrawn for safety reasons.
55. Role of Phase 4 in accelerated approvals
◦ After granting accelerated approval for such drug, the post marketing trials shall be required to
validate the anticipated clinical benefit.
◦ If the remarkable efficacy is observed with a defined dose in the Phase II clinical trial of
investigational new drug for the unmet medical needs of serious and life threatening diseases in
the country, it may be considered for grant of marketing approval by the Central Licensing
Authority based on Phase II clinical trial data.
◦ In such cases, additional post licensure studies may be required to be conducted after approval
to generate the data on larger population to further verify and describe the clinical benefits, as
per the protocol approved by the Central Licensing Authority.
56. SEEDING TRIAL
◦ Seeding trials are clinical studies designed by pharmaceutical companies with primary
intention to promote the use of drugs that were recently approved or are under review by
regulatory authorities.
◦ The purpose is
To ‘seed’ the habit of prescribing the new drug into the trial investigators.
To trigger a ‘switch’ of brands from a competitor product to the new drug, thereby
increasing volume of sales.
To convert the investigators into brand ambassadors.
57. ◦ Adverse impacts:
Quality is not reliable and the scientific validity and utility are usually limited.
Physicians are manipulated into prescribing and promoting the drug.
Lead to general mistrust of healthcare providers by society at large.
◦ Some well-known seeding studies are STEPS (Study of Neurontin: Titration to Effectiveness
and Profile of Safety) and ADVANTAGE trial (Assessment of Differences between Vioxx and
Naproxen to Ascertain Gastrointestinal Tolerability and Effectiveness).
◦ Hence these trials should be identified and discouraged by IRB/IEC.
58. REFERENCES
1. Guidelines for good clinical practice (GCP) for trials on pharmaceutical products.
2. Goodman & Gilman’s Pharmacological basis of therapeutics.
3. Glasser SP, Salas M, Delzell E. Importance and Challenges of Studying Marketed Drugs: What Is a Phase IV Study? Common Clinical
Research Designs, Registries, and Self-Reporting Systems. J Clin Pharmacol. 2007 Sep;47(9):1074–86.
4. Song JW, Chung KC. Observational Studies: Cohort and Case-Control Studies: Plast Reconstr Surg. 2010 Dec;126(6):2234–42.
5. Grimsrud KN, Sherwin CMT, Constance JE, Tak C, Zuppa AF, Spigarelli MG, et al. Special population considerations and regulatory
affairs for clinical research. Clin Res Regul Aff. 2015 Apr 3;32(2):45–54.
6. Zhang X, Zhang Y, Ye X, Guo X, Zhang T, He J. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status
report from the ClinicalTrials.gov registry. BMJ Open. 2016 Nov;6(11):e010643.
InVitro Drug Metabolism- and Transporter-Mediated Drug-Drug Interaction Studies focuses on how to assess the DDI potential of a drug in vitro and how to use the results from those assessments to inform clinical DDI studies.